TransCode Therapeutics, Inc. (RNAZ)

TransCode Therapeutics Statistics

Total Valuation

RNAZ has a market cap or net worth of $11.81 million. The enterprise value is $2.81 million.

Market Cap	11.81M
Enterprise Value	2.81M

Important Dates

The next estimated earnings date is Thursday, November 13, 2025, after market close.

Earnings Date	Nov 13, 2025
Ex-Dividend Date	n/a

Share Statistics

RNAZ has 833,683 shares outstanding.

Current Share Class	833,683
Shares Outstanding	833,683
Shares Change (YoY)	n/a
Shares Change (QoQ)	+383.95%
Owned by Insiders (%)	0.15%
Owned by Institutions (%)	4.04%
Float	832,425

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.66
P/TBV Ratio	1.66
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.27

Current Ratio	5.27
Quick Ratio	4.82
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1,150.02

Financial Efficiency

Return on equity (ROE) is -658.62% and return on invested capital (ROIC) is -237.91%.

Return on Equity (ROE)	-658.62%
Return on Assets (ROA)	-139.89%
Return on Invested Capital (ROIC)	-237.91%
Return on Capital Employed (ROCE)	-218.61%
Revenue Per Employee	n/a
Profits Per Employee	-$3.51M
Employee Count	7
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -97.26% in the last 52 weeks. The beta is 1.51, so RNAZ's price volatility has been higher than the market average.

Beta (5Y)	1.51
52-Week Price Change	-97.26%
50-Day Moving Average	10.83
200-Day Moving Average	49.10
Relative Strength Index (RSI)	71.84
Average Volume (20 Days)	354,591

Short Selling Information

The latest short interest is 58,692, so 7.04% of the outstanding shares have been sold short.

Short Interest	58,692
Short Previous Month	68,937
Short % of Shares Out	7.04%
Short % of Float	7.05%
Short Ratio (days to cover)	5.12

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-14.65M
Pretax Income	-24.60M
Net Income	-24.60M
EBITDA	-14.60M
EBIT	-14.65M
Earnings Per Share (EPS)	-$94.05

Balance Sheet

The company has $7.37 million in cash and n/a in debt, giving a net cash position of $7.37 million or $8.85 per share.

Cash & Cash Equivalents	7.37M
Total Debt	n/a
Net Cash	7.37M
Net Cash Per Share	$8.85
Equity (Book Value)	6.15M
Book Value Per Share	7.37
Working Capital	6.68M

Cash Flow

In the last 12 months, operating cash flow was -$14.35 million and capital expenditures -$13,370, giving a free cash flow of -$14.36 million.

Operating Cash Flow	-14.35M
Capital Expenditures	-13,370
Free Cash Flow	-14.36M
FCF Per Share	-$17.23

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

RNAZ does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-241.46%
FCF Yield	-140.99%

Analyst Forecast

The average price target for RNAZ is $280.00, which is 1,876.01% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$280.00
Price Target Difference	1,876.01%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 15, 2025. It was a reverse split with a ratio of 1:28.

Last Split Date	May 15, 2025
Split Type	Reverse
Split Ratio	1:28

Scores

Altman Z-Score	n/a
Piotroski F-Score	2